Minerva Neurosciences, Inc (NERV): Price and Financial Metrics
GET POWR RATINGS... FREE!
NERV Stock Price Chart Interactive Chart >
NERV Price/Volume Stats
| Current price | $1.69 | 52-week high | $15.27 |
| Prev. close | $1.59 | 52-week low | $1.26 |
| Day low | $1.56 | Volume | 25,800 |
| Day high | $1.70 | Avg. volume | 84,543 |
| 50-day MA | $2.17 | Dividend yield | N/A |
| 200-day MA | $4.13 | Market Cap | 9.02M |
Minerva Neurosciences, Inc (NERV) Company Bio
Minerva Neurosciences, Inc. focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company was founded in 2007 and is based in Waltham, Massachusetts.
Latest NERV News From Around the Web
Below are the latest news stories about MINERVA NEUROSCIENCES INC that investors may wish to consider to help them evaluate NERV as an investment opportunity.
Minerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2022 Earnings Call TranscriptMinerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2022 Earnings Call Transcript March 8, 2023 Operator: Good day, and thank you for standing by. Welcome to Minerva Neurosciences Full Year 2022 Financial Results and Business Update Conference Call. Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your […] |
Q4 2022 Minerva Neurosciences Inc Earnings CallQ4 2022 Minerva Neurosciences Inc Earnings Call |
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business UpdatesCompany to Host Conference Call Today at 8:30 a.m. ETBURLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2022. Corporate Update “In 2022, we had multiple interactions with the FDA regarding the regulatory path forward for o |
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023Management to Host Conference CallBURLINGTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release fiscal year 2022 financial results and business updates on Wednesday, March 8, 2023. The Company will host a webcast that day at 8:30 a.m. Eastern Time to discuss the results and updates. The live co |
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDAMinerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect. |
NERV Price Returns
| 1-mo | N/A |
| 3-mo | -33.98% |
| 6-mo | -81.89% |
| 1-year | -73.44% |
| 3-year | -95.69% |
| 5-year | -96.70% |
| YTD | 6.29% |
| 2022 | -75.19% |
| 2021 | -65.77% |
| 2020 | -67.09% |
| 2019 | 5.49% |
| 2018 | 11.40% |
Loading social stream, please wait...